Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Anlotinib Maintenance Retreatment in PSR Ovarian Cancer
NCT05385068Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of niraparib and anlotinib in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression Free Survival at 1 year. Status: unknown.
02
Drugs
niraparibanlotinib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT05385068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385068.